Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

Imatinib Mesylate 41Sunitinib 17nilotinib 12regorafenib 10ripretinib 6avapritinib 6Leucovorin 3Ipilimumab 3Gemcitabine 3Dasatinib 3CTLA-4 Antigen 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2Paclitaxel 2Oxaliplatin 2Midazolam 2Irinotecan 2Fluorouracil 2Floxuridine 2Erlotinib Hydrochloride 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2Biopsy, Fine-Needle 2Bevacizumab 2vatalanib 1umbralisib 1trametinib 1tinostamustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Stromal Tumors × Sorafenib × Clear all
NCT01091207 2012-01-20

Sorafenib for Imatinib/Sunitinib-failed GIST

Samsung Medical Center

Phase 2 Completed
39 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡